Results 251 to 260 of about 1,730,139 (304)

Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2). [PDF]

open access: yesBioorg Chem
da Silva Zanzarini I   +14 more
europepmc   +1 more source

The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target. [PDF]

open access: yesCancer Cell Int
Alkafaas SS   +15 more
europepmc   +1 more source

Cancer Resistance in Amphibians

Alternatives to Laboratory Animals, 2007
While spontaneous tumours may occasionally develop in inbred and isogenic strains of Xenopus laevis, the South African clawed toad, they are extremely rare in natural and laboratory populations. Only two amphibian neoplasms, the renal adenocarcinoma of Rana pipiens and the lymphosarcoma of Xenopus laevis, have been extensively explored. Amphibians are
Laurens N, Ruben   +2 more
openaire   +2 more sources

Multidrug Resistance in Cancer

Scientific American, 1989
Chemotherapy often fails because a tumor develops resistance to an array of different drugs. A single glycoprotein turns out to be responsible: it proliferates in some cells and pumps out the drugs. Now that the protein pump has been identified it may be possible to interfere with its action or to make it the target for drugs that destroy the cancer ...
N, Kartner, V, Ling
openaire   +2 more sources

Anthracycline-resistant breast cancer

Breast Cancer, 1997
The management of breast cancer requires the judicious use of cytotoxic therapy, hormone therapy, radiotherapy, analgesics, and other forms of physical and psychological support for optimal palliation of symptoms and prolongation of survival. Patients with low-risk metastatic breast cancer often benefit from hormone therapy as initial management; other
, Hortobagyi, , Pivot, , Asmar
openaire   +2 more sources

Drug Resistance and Cancer

1993
Systemic therapy with cytotoxic drugs is the basis of most effective treatments of disseminated cancers. Additionally, adjuvant chemotherapy can offer a significant survival advantage to selected patients following the treatment of localized disease with surgery or radiotherapy, presumably by eliminating undetected minimal or microscopic metastatic ...
C S, Morrow, K, Cowan
openaire   +2 more sources

Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells

International Journal of Gynecological Cancer, 2005
Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. This study investigates the role of BCRP in resistance of ovarian cancer to TPT treatment.
P, Jia   +10 more
openaire   +2 more sources

HOST RESISTANCE TO CANCER*

Australian and New Zealand Journal of Surgery, 1967
Summary1. Experimental studies on immunity to tumours in animals show that tumour growth is modified by an immunological reaction provided that the immunological system of the host is intact and the tumour carries antigens which are different to those of the host and therefore recognizably “foreign.”2.
openaire   +2 more sources

Home - About - Disclaimer - Privacy